These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23885913)

  • 1. Positron emission tomography/CT after yttrium-90 radioembolization: current and future applications.
    Gates VL; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2013 Aug; 24(8):1153-5. PubMed ID: 23885913
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
    Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
    J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; Qiu D; Kitajima H; Mittal PK; Kim HS
    Abdom Imaging; 2014 Oct; 39(5):969-78. PubMed ID: 24740759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic activity assessment by
    Kim DY; Lee HW; Kang W; Kim GM; Won JY; Yun M
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1679-1684. PubMed ID: 33226706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superselective yttrium-90 radioembolization for hepatocellular carcinoma in high-risk cases: another tool in the toolbox.
    Brown KT
    J Vasc Interv Radiol; 2014 Jul; 25(7):1073-4. PubMed ID: 24968727
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
    Kousik V; Promila P; Verma R; Gupta A
    Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 90Y Liver Radioembolization Imaging Using Amplitude-Based Gated PET/CT.
    Osborne DR; Acuff S; Neveu M; Kaman A; Syed M; Fu Y
    Clin Nucl Med; 2017 May; 42(5):373-374. PubMed ID: 28240669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Radioembolization with (90)Y-microspheres for liver tumors].
    Rodríguez-Fraile M; Iñarrairaegui M
    Rev Esp Med Nucl Imagen Mol; 2015; 34(4):244-57. PubMed ID: 25911062
    [No Abstract]   [Full Text] [Related]  

  • 10. Intraprocedural yttrium-90 positron emission tomography/CT for treatment optimization of yttrium-90 radioembolization.
    Bourgeois AC; Chang TT; Bradley YC; Acuff SN; Pasciak AS
    J Vasc Interv Radiol; 2014 Feb; 25(2):271-5. PubMed ID: 24461132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apparent diffusion coefficient quantification as an early imaging biomarker of response for unresectable infiltrative hepatocellular carcinoma.
    Sivrioglu AK; Kara K; Kafadar C; Mutlu H
    Abdom Imaging; 2015 Aug; 40(6):1470. PubMed ID: 25399233
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatopulmonary shunting in patients with primary and secondary liver tumors scheduled for radioembolization.
    Powerski MJ; Erxleben C; Scheurig-Münkler C; Geisel D; Heimann U; Hamm B; Gebauer B
    Eur J Radiol; 2015 Feb; 84(2):201-7. PubMed ID: 25483014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
    Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
    J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.
    Iñarrairaegui M; Thurston KG; Bilbao JI; D'Avola D; Rodriguez M; Arbizu J; Martinez-Cuesta A; Sangro B
    J Vasc Interv Radiol; 2010 Aug; 21(8):1205-12. PubMed ID: 20598574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
    Edeline J; Crouzet L; Campillo-Gimenez B; Rolland Y; Pracht M; Guillygomarc'h A; Boudjema K; Lenoir L; Adhoute X; Rohou T; Boucher E; Clément B; Blanc JF; Garin E
    Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):635-43. PubMed ID: 26455499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 90Yttrium PET/MR-based dosimetry after liver radioembolization (SIRT).
    Wissmeyer M; Delattre BM; Zaidi H; Terraz S; Ratib O
    Clin Nucl Med; 2015 Apr; 40(4):355-7. PubMed ID: 25674869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
    Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
    J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization.
    Xing M; Kokabi N; Camacho JC; Kim HS
    BMC Cancer; 2018 Jan; 18(1):75. PubMed ID: 29329568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of temporary protective embolization of normal liver tissue using degradable starch microspheres during radioembolization of liver tumours.
    Meyer C; Pieper CC; Ezziddin S; Wilhelm KE; Schild HH; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):231-7. PubMed ID: 24030669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis.
    Jia Z; Jiang G; Tian F; Zhu C; Qin X
    Saudi J Gastroenterol; 2016; 22(5):353-359. PubMed ID: 27748320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.